Efficacy and Safety in Chinese Patients With IgA Nephropathy Who Have Completed Study Nef-301
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy
and safety of Nefecon treatment in Chinese patients who have completed Nef-301 and continue
to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs).